New drug aims to melt liver fat and stop scarring in MASH patients
NCT ID NCT07631637
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests an experimental drug called ALN-CIDEB in 150 adults with MASH, a serious liver disease involving fat buildup and scarring. The goal is to see if the drug can reduce liver fat, injury, and scarring compared to a placebo. Participants will receive either the drug or a placebo and be monitored for side effects and changes in liver health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALN-CIDEB
- What this could lead to
- If it works, this could point toward a treatment that reduces liver fat and scarring in people with MASH, potentially slowing or stopping liver damage.
- What could go wrong
- This is an early Phase 2b trial with only 150 people, so results may not apply to everyone. The drug may cause side effects or fail to improve liver health better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROTIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Can a single gene therapy injection reverse fatty liver disease?
- Navy beans take on fatty liver: a diet swap put to the test
- Could a tailored diet make a MASH drug work better?
- New injections aim to melt liver fat in MASH patients
- New shot aims to reverse liver scarring in MASH patients